Retatrutide and Fatty Liver (MASLD): What the Liver Fat Data Shows

The retatrutide fatty liver data come from one 98-person Phase 2 MRI study. In it, liver fat fell 82.4% on average over 24 weeks on 12 mg, and 86% of that group ended with normal liver fat, under 5%. That is fat on a scan. The study took no liver biopsies, so nobody knows yet whether the inflammation and scarring of MASH improved, and the Phase 3 trial built to answer that has an estimated primary completion of August 2030. As of October 2026 no approved version of retatrutide exists.

What MASLD and MASH mean

Fatty liver disease got new names in 2023. A global panel led by the major US, European and Latin American liver societies renamed NAFLD as MASLD, metabolic dysfunction-associated steatotic liver disease, partly because many panelists found "nonalcoholic" and "fatty" stigmatizing. MASLD means fat has built up in the liver alongside at least 1 of 5 cardiometabolic risk factors, such as excess weight, type 2 diabetes or high blood pressure.

MASH, metabolic dysfunction-associated steatohepatitis, replaced NASH. It is MASLD plus inflammation and liver cell injury, the stage that can drive scarring (fibrosis) and, over years, cirrhosis.

That split is the key to reading the retatrutide data. The study measured fat precisely, not the inflammation or scarring that decide long-term liver health.

What the retatrutide fatty liver study measured

It came from inside a larger weight-loss trial. The 48-week Phase 2 obesity trial enrolled 338 adults with obesity or overweight and no type 2 diabetes. Of those, 98 had at least 10% liver fat on MRI-PDFF, a scan that measures what share of the liver is fat, and joined a liver substudy published in Nature Medicine in 2024.

They were randomly assigned to placebo or to 1, 4, 8 or 12 mg of retatrutide once a week, with doses stepped up every 4 weeks. At the start they averaged 46.6 years old and a BMI of 38.4. Everyone got diet and activity counseling.

Average relative change in liver fat on MRI, and weight change in the same people; normal means under 5%. Source: Sanyal et al., Nature Medicine 2024.

Every dose beat placebo at 24 weeks, the main endpoint. In the 8 mg and 12 mg rows, both groups had lost about 18% of their weight by then and cut liver fat by about 82%. Liver fat following weight runs through the whole study.

Does retatrutide get rid of fatty liver?

On MRI, for most people on higher doses, yes. By week 24, liver fat was under 5% in 79% of people on 8 mg and 86% on 12 mg, against none on placebo. By week 48 those shares were 89% and 93%.

Smaller drops counted too. At 24 weeks, 71% to 100% of people on retatrutide had cut liver fat by at least 30%, against 4% on placebo. In a 2021 analysis of 7 early-phase MASH trials, people who crossed that line were far more likely to improve on biopsy (51% versus 14%).

Three details help if you're tracking your own liver:

• It clears early. Most of the drop came in the first 24 weeks and held through week 48 in people still on treatment, though only 43.9% had a usable 48-week scan.
• It clears before your weight does. People who reached normal liver fat by week 24 still had an average BMI of 31.0 to 32.9, and by week 48 that range had fallen to 25.8 to 30.8.
• Stopping is a blind spot. Liver fat wasn't measured after treatment ended, and some weight came back within 4 weeks of the last dose.

Our read: Phase 3 weight loss runs bigger than the Phase 2 substudy's. In TRIUMPH-1, adults without diabetes on 12 mg lost 28.3% of body weight over 80 weeks (efficacy estimand; 25.0% counting everyone randomized), against 25.9% at 48 weeks in the substudy. The Phase 2 liver fat curve flattened at around 20% weight loss, so people who stay on a high dose may well clear their liver fat too, because liver fat tracked weight in the substudy. That's an inference: no Phase 3 trial has reported liver fat.

Why liver fat follows weight loss, and where glucagon fits

Weight loss explains most of the liver fat drop. The fall in liver fat tracked weight loss closely (a correlation of 0.80 at 24 weeks, where 1.0 is a perfect match) and deep belly fat loss almost as closely (0.79). It leveled off at around 20% weight loss, near the floor of how much fat a liver can shed. Metabolic markers moved with it: by week 48, fasting insulin had fallen by up to 70.9%, and triglycerides had fallen 49.4% on 12 mg. The belly fat page covers the Phase 3 waist data.

This study can't split the two effects. The authors say retatrutide's edge may come from bigger weight loss, from glucagon acting on the liver, or both.

What the MRI can't tell you about MASH

Liver fat is not the same as liver damage. MRI-PDFF sees fat, not inflammation or scarring, and the study took no liver biopsies, which is how MASH trials confirm the disease and grade fibrosis. Most participants also had early disease: only 7 of 98 had a FIB-4 score above 1.3 or an ELF score above 9.8, cutoffs used to rule out advanced scarring.

The study was also small, US-only and 98.0% white, made no statistical correction for running many tests, and the authors call the results "hypothesis-generating and not definitive." Lilly designed, funded and ran it. If you have type 2 diabetes, this study doesn't speak to you directly; the clinical trials page lists the diabetes trials that did include you.

Retatrutide vs tirzepatide and semaglutide for the liver

On liver fat alone, retatrutide's numbers are bigger. The Nature Medicine authors cite reported drops of about 47% after 52 weeks for tirzepatide and about 50% after 72 weeks for semaglutide, against 86% at 48 weeks on retatrutide 12 mg. They warn that different populations and designs limit the comparison.

The evidence gap runs the other way. Tirzepatide and semaglutide have biopsy results in people with MASH and scarring. Retatrutide doesn't.

Biopsy evidence is what earned today's MASH treatments their approvals. The FDA approved resmetirom (Rezdiffra) for noncirrhotic MASH with moderate to advanced fibrosis in March 2024 and granted semaglutide (Wegovy) accelerated approval for the same group in August 2025. The tirzepatide comparison covers the weight-loss side, where TRIUMPH-5 is still pending as of October 31, 2026.

Our read: bigger liver fat numbers don't make retatrutide the better MASH drug. Until biopsy or outcome data exist, tirzepatide and semaglutide are the ones with proof of benefit on inflammation and scarring.

Is retatrutide safe for your liver?

In the Phase 2 trial, no liver warning sign appeared. In the liver substudy, average ALT and AST started in the normal range and did not change consistently compared with placebo. The authors found no sign of drug-induced liver injury in the full Phase 2 trial through 48 weeks. Lilly also ran a Phase 1 study in 43 people with impaired and normal liver function (NCT05916560). It is completed, and no results had been posted as of October 31, 2026, so there's no public guidance yet for people with cirrhosis.

The common side effects were digestive, mostly at 8 and 12 mg. In TRIUMPH-1, 42.4% of people on 12 mg had nausea, against 14.8% on placebo, and 11.3% stopped because of side effects, against 4.9% on placebo; our guide to managing nausea covers what helps. One person in the liver substudy developed acute gallbladder inflammation and had the gallbladder removed, a known class risk: tirzepatide's label lists gallbladder disease among its warnings. If you drink, the alcohol page covers what's known.

The liver injury headlines are a different story. On June 19, 2026, the Chief Health Officer of Victoria, Australia, reported six cases of acute liver injury since January 2026 in people using unapproved products labelled Retatrutide, Reta, R-10 or R-20, bought online, through friends or on social media. The department suspects a contaminant, and the alert was still active and unchanged on October 31, 2026.

Those cases don't show what pure retatrutide does, and the trials don't show what is in a vial bought online. If you're weighing retatrutide for sale listings, that gap is the point: none of them is the product used in these trials, and Lilly says retatrutide "cannot be legally sold or marketed for human use." For the full safety picture, see whether retatrutide is safe.

What comes next for retatrutide and MASH

The real test for MASH has already started. SYNERGY-Outcomes, a Phase 3 trial that began in October 2025, is enrolling about 4,500 adults with higher-risk MASLD, picked by scans and blood tests rather than biopsy: at least 8% liver fat, an ELF score of 9 to 10.8 and raised liver stiffness (10 kPa or more, under 20 kPa). Within one master protocol, retatrutide and tirzepatide are each tested against placebo for about 224 weeks. The main question is whether treatment delays serious outcomes such as cirrhosis, fluid buildup in the belly, bleeding varices, a liver transplant or death, with liver fat, stiffness and ELF also checked at week 104. The registry lists primary completion in August 2030, so answers are years away.

On ClinicalTrials.gov on October 31, 2026, SYNERGY-Outcomes listed 563 sites in 34 countries or territories, 502 of them recruiting, with 137 recruiting in the US. The clinical trials page tracks the rest of the program, and the near me page covers finding a US site by state.

Lilly's Phase 3 releases, most recently the October 28 head-to-head result against Ozempic, have reported weight, blood sugar, knee pain and sleep apnea, and we found no liver figures in them. On filing, Lilly last said, on September 29, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA). On October 2, 2026, the FDA decided that retatrutide is a drug, not a biological product, so an application would need to be filed under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly's appeal on that question is pending in the Seventh Circuit, and we found no ruling as of October 31, 2026. The FDA approval page tracks it.

What you can do now depends on where your liver stands:

• Fatty liver without known scarring: weight loss is still the lever, and your liver may respond before you reach a goal weight. Ask your doctor about a FIB-4 or ELF test, which the study authors call well-validated for estimating scarring risk.
• MASH with moderate or advanced scarring: approved treatments already exist, so ask about them now rather than waiting for 2030.
• Wanting retatrutide through a legal route: ask about SYNERGY-Outcomes, which is recruiting. The other route is single-patient expanded access, which your doctor requests from Lilly for adults with a BMI of 35 or more and at least 2 serious obesity-related complications who haven't responded to approved treatments and can't join a trial. The how to get retatrutide page walks through both.